Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01269047 · ClinicalTrials.gov registry record · Phase 4
Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
A Phase 4 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
NCT01269047 is a Phase 4 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 37 participants.
The verdict
NCT01269047, a Phase 4 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
Study Summary
The main purpose of the study is to determine the effects of 16 weeks of adjunctive pramlintide or exenatide use on glycemic control in Type 1 Diabetes.
Interventions
- DRUG Insulin
- DRUG Exenatide
- DRUG Pramlintide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2009-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01269047
The ClinicalTrials.gov registry entry for NCT01269047 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Insulin is the first listed.
NCT01269047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01269047 about?
NCT01269047 is a clinical study titled "Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia". The main purpose of the study is to determine the effects of 16 weeks of adjunctive pramlintide or exenatide use on glycemic control in Type 1 Diabetes.
What is the current status of trial NCT01269047?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2009-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01269047?
The interventions under investigation include: Insulin (DRUG), Exenatide (DRUG), Pramlintide (DRUG).
Who is sponsoring clinical trial NCT01269047?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.